Answering More of Your Top 340B Questions

Answering More of Your Top 340B Questions

From 340B Insight by 340B Health

February 9, 2026 · 14 min

About this episode

The episode addresses listener questions about the 340B program, focusing on the CMS drug acquisition cost survey and state legislative actions for 2026.

For the third year in a row, we consulted 340B Health’s experts on our staff to answer our listeners’ most pressing 340B questions. As 2026 gets underway, we answer your questions about the CMS drug acquisition cost survey, what states are doing on 340B this year, and more. Some of the topics we cover: CMS Drug Acquisition Cost Survey Not Mandatory Earlier this year, the Center for Medicare & Medicaid Services (CMS) launched a new survey focusing on hospitals’ outpatient drug acquisition costs, which could lead to Medicare Part B payment cuts for 340B drugs. Some hospitals recently saw materials suggesting they are required to complete the survey. Amanda Nagrotsky, vice president of legal and policy for 340B Health, notes that a CMS rule states there are no penalties under the Medicare statute for hospitals that choose not to respond. 340B Health and other groups sent a joint letter asking for the language to be corrected, citing the confusion it has caused. State Legislatures Are Becoming Major Battlegrounds for 2026 Just over one month into 2026, statehouses are already shaping up to be one of the biggest venues to debate various aspects of the 340B. Two broad categories of…

Topics covered

  • 340B program
  • CMS drug acquisition cost survey
  • state legislation
  • healthcare policy
  • Medicare Part B payment cuts

Keywords

  • 340B
  • CMS
  • drug acquisition costs
  • Medicare
  • state legislation
  • contract pharmacy
  • health policy

Mentioned in this episode

Organizations: 340B Health, Center for Medicare & Medicaid Services

More episodes of 340B Insight

Explore listener stats, chart rankings, contacts and more on the 340B Insight podcast page.